Activity Overview
This online, on-demand virtual symposium brings together renowned experts in advanced non–small cell lung cancer (NSCLC). In this educational program, these experts use real-world scenarios to guide learners through best practices in biomarker testing and the application of current and emerging targeted therapies for advanced NSCLC. A multidisciplinary faculty panel debates therapeutic decision-making, addresses resistance and sequencing strategies, and highlights proactive management of adverse events to support the safe, effective use of these vital agents.
This educational activity is an archive of the live symposium held on February 21, 2026.
Target Audience
These activities are intended for oncologists and other oncology health care professionals interested in the latest advances in the diagnosis, treatment, and management of lung cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply best practices for molecular testing to identify actionable mutations in clinical practice
- Evaluate recent data on current and emerging targeted therapies for advanced NSCLC
- Incorporate molecular testing results alongside patient- and disease-specific characteristics to design personalized treatment plans for advanced NSCLC
Narjust Florez, MD, FASCO
Associate Director, Cancer Care Equity Program
Codirector, Young Lung Cancer Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Bristol Myers Squibb, Caris Life Sciences, Catalyst Pharmaceuticals, Daiichi Sankyo, EMD Serono, Genentech, Jazz Pharmaceuticals, Johnson & Johnson, Lilly, Merck, Mirati Therapeutics, Novartis, Nuvalent, Nuvation Bio, Pfizer, Regeneron, Sanofi, Takeda Pharmaceuticals; Speakers Bureau: ASCO Post, Clinical Care Options, CME Outfitters, DAVA Oncology; Grant/Research Funding: American Society of Clinical Oncology, AstraZeneca, Champa Fund for Early Cancer Detection, Daiichi Sankyo, Genentech, GO2 for Lung Cancer, International Association for the Study of Lung Cancer, Johnson & Johnson, LUNGevity Foundation, Pfizer, Women’s Health Access Matters Foundation
David P. Carbone, MD, PhD
Professor, Department of Internal Medicine
Director, James Thoracic Oncology Center
The Ohio State University Comprehensive Cancer
Center
Columbus, OH
Disclosures: Advisory Boards: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, DAVA, EMD Serono, Gilead, Iovance, Janssen Global Services, LLC, Johnson & Johnson, Lilly, Lumanity, Merck, Merck KGaA, Natera, OncoHost, Pfizer, Regeneron, Roche, Synthekine Inc., Taiho Oncology, Tempus, Veracyte
Edward B. Garon, MD, MS
Professor
Director, Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director, Signal Transduction and
Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, ArriVent BioPharma, AstraZeneca, Bayer, Bicycle Therapeutics, Black Diamond Therapeutics, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, GSK, I-Mab, Hexagon, iTeos, LianBio, Merck, Novartis, Nuvalent, Oxford Bio, Pfizer, Regeneron, Samsung, Sanofi, Servier, Strata, Synthekine, TransCode, Verastem; Grant/Research Funding: ABL Bio, ArriVent BioPharma, AstraZeneca, Bayer, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, Gilead Sciences, Iovance Biotherapeutics, Merck, Novartis, Prelude, Regeneron, Synthekine, TILT Biotherapeutics
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.